Brainstorm Cell Therapeutics (BCLI) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
BrainStorm Cell Therapeutics Reports Third Quarter 2015 Financial Results And Provides Corporate Update
November 17, 2015 7:00 AM ESTHACKENSACK, N.J. and PETACH TIKVAH, Israel, Nov. 17, 2015 /PRNewswire/ --Â BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the third quarter ended September 30, 2015.
"2015 continues to be a year of important advances in our clinical and corporate programs," stated BrainStorm's CEO, Chaim Lebovits. "Specifically, we are making significant progress in the ongoing development program of our lead development candidate,... More
